A New Paradigm to Indicate Antidepressant Treatments.
antidepressants
depression
forebrain
habenula
mood disorders
natural resilience
neural circuits
placebo
treatment
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
10 Dec 2021
10 Dec 2021
Historique:
received:
30
10
2021
revised:
30
11
2021
accepted:
04
12
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
This article develops the idea that clinical depression can be seen as a typical human response, largely rooted in human culture, to events of loss or times of adversity. Various biological, psychological, and social factors may cause some individuals to have a depressive reaction that is ineffectually limited in time and/or severity. Recovery occurs mainly based on natural resilience mechanisms, which come into play spontaneously, but which are sometimes inhibited or blocked by specific pathological biopsychosocial mechanisms. One of the mechanisms for this could be the influence of the circuits that regulate pleasure and happiness, along the dorsal diencephalic connection (DDC) pathway from the forebrain to the midbrain via the habenula. Therapy works by undermining the biopsychosocial factors that prevent the natural recovery mechanism from working. Treatment should, therefore, be seen as facilitating rather than causing natural recovery. This approach is in line with the high recovery rate after placebo treatments and the positive influence of pharmacological treatments with completely different sites of action. Acceptance of this model means that when studying new treatments for depression, a new paradigm must be applied in which the relative value of antidepressant treatment is specifically weighted in terms of enabling the natural resilience process.
Identifiants
pubmed: 34959688
pii: ph14121288
doi: 10.3390/ph14121288
pmc: PMC8705982
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurosurg Focus. 2007;23(1):E13
pubmed: 17961058
Psychopharmacology (Berl). 1986;90(1):131-8
pubmed: 2876451
Hum Psychopharmacol. 2021 Nov 17;:e2826
pubmed: 34788473
Med Hist. 2011 Jul;55(3):393-9
pubmed: 21792267
Acta Neuropsychiatr. 2018 Feb;30(1):29-42
pubmed: 28473012
Dialogues Clin Neurosci. 2015 Mar;17(1):31-41
pubmed: 25987861
Hist Psychiatry. 2019 Mar;30(1):3-18
pubmed: 30299163
Am J Psychiatry. 2017 Feb 1;174(2):102-109
pubmed: 27523503
Eur Neuropsychopharmacol. 2016 Jun;26(6):979-93
pubmed: 27139079
J Affect Disord. 1990 Apr;18(4):289-99
pubmed: 2140382
J Clin Psychiatry. 2007 Aug;68(8):1195-205
pubmed: 17854243
Psychiatry. 2007 Spring;70(1):30-51
pubmed: 17492910
Front Pharmacol. 2019 Dec 19;10:1462
pubmed: 31956308
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Arch Gen Psychiatry. 1984 Aug;41(8):782-6
pubmed: 6378117
Dialogues Clin Neurosci. 2015 Mar;17(1):59-67
pubmed: 25987864
Eur Arch Psychiatry Clin Neurosci. 2008 Jun;258 Suppl 2:1-2
pubmed: 18516509
World Psychiatry. 2020 Oct;19(3):381-388
pubmed: 32931122
Rev Psiquiatr Salud Ment. 2014 Oct-Dec;7(4):186-94
pubmed: 24486358
J Psychopharmacol. 2018 Dec;32(12):1277-1285
pubmed: 30255719